ZTS Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 май 2024 @ 23:00):

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally...

Stats
Объем за сегодня	2.57M
Средний объем	3.68M
Рыночная капитализация	76.41B
EPS	$0 ( 2024-05-02 )
Дата следующего отчета о доходах	( $1.340 ) 2024-05-22
Last Dividend	$0.375 ( 2023-10-31 )
Next Dividend	$0 ( N/A )
P/E	32.95
ATR14	$0.100 (0.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Lagano Roxanne	Sell	923	Common Stock
2024-04-05	Lagano Roxanne	Buy	281	Phantom Stock Unit
2024-04-05	Mamilli Wafaa	Buy	411	Phantom Stock Unit
2024-04-05	Joseph Wetteny	Buy	581	Phantom Stock Unit
2024-04-05	Driscoll Rimma	Buy	16	Phantom Stock Unit

INSIDER POWER
-16.30
Last 100 transactions
Buy: 87 523 \| Sell: 122 271

Объем Корреляция

Длинно: -0.73 (moderate negative)

Кратко: -0.54 (weak negative)

Signal:(21.389) Neutral

Zoetis Inc Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Zoetis Inc Корреляция - Валюта/Сырье

-0.52
( weak negative )

-0.69
( moderate negative )

0.00
( neutral )

0.06
( neutral )

-0.55
( weak negative )

0.77
( moderate )

Zoetis Inc Финансовые показатели

Annual	2023
Выручка:	$8.54B
Валовая прибыль:	$5.83B (68.28 %)
EPS:	$5.08

FY	2023
Выручка:	$8.54B
Валовая прибыль:	$5.83B (68.28 %)
EPS:	$5.08

FY	2022
Выручка:	$8.08B
Валовая прибыль:	$5.63B (69.63 %)
EPS:	$4.51

FY	2021
Выручка:	$7.78B
Валовая прибыль:	$5.47B (70.38 %)
EPS:	$4.28

Financial Reports:

No articles found.

Zoetis Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.325 (N/A)	$0.325 (N/A)	$0.375 (N/A)	$0.375 (N/A)	$0.375 (N/A)	$0.375 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Zoetis Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.25 - Stable (5.00%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0650	2013-04-29
Last Dividend	$0.375	2023-10-31
Next Dividend	$0	N/A
Payout Date	2023-12-01
Next Payout Date	N/A
# dividends	43	--
Total Paid Out	$7.38	--
Avg. Dividend % Per Year	0.50%	--
Score	4.48	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.25
Div. Directional Score	7.83	--

Next Divdend (Est)
(2024-07-18)

$0.386 Estimate 39.27 %

Dividend Stability

0.79 Good

Dividend Score

4.48

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2013	$0.195	0.63%
2014	$0.288	0.89%
2015	$0.332	0.77%
2016	$0.380	0.80%
2017	$0.420	0.78%
2018	$0.504	0.70%
2019	$0.656	0.78%
2020	$0.800	0.60%
2021	$1.000	0.61%
2022	$1.300	0.56%
2023	$1.500	1.02%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.274	1.500	4.52	6.79	[0 - 0.5]
returnOnAssetsTTM	0.167	1.200	4.45	5.33	[0 - 0.3]
returnOnEquityTTM	0.484	1.500	5.73	8.60	[0.1 - 1]
payoutRatioTTM	0.217	-1.000	7.83	-7.83	[0 - 1]
currentRatioTTM	3.33	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	1.712	0.800	4.64	3.71	[0.8 - 2.5]
cashRatioTTM	1.035	1.500	5.36	8.05	[0.2 - 2]
debtRatioTTM	0.459	-1.500	2.35	-3.52	[0 - 0.6]
interestCoverageTTM	13.29	1.000	6.19	6.19	[3 - 30]
operatingCashFlowPerShareTTM	5.24	2.00	8.25	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.82	2.00	8.09	10.00	[0 - 20]
debtEquityRatioTTM	1.302	-1.500	4.79	-7.19	[0 - 2.5]
grossProfitMarginTTM	0.692	1.000	1.800	1.800	[0.2 - 0.8]
operatingProfitMarginTTM	0.368	1.000	4.63	4.63	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.364	1.000	9.09	9.09	[0.2 - 2]
assetTurnoverTTM	0.609	0.800	9.28	7.42	[0.5 - 2]
Total Score				10.41

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	32.00	1.000	6.87	0	[1 - 100]
returnOnEquityTTM	0.484	2.50	7.26	8.60	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.82	2.00	8.73	10.00	[0 - 30]
dividendYielPercentageTTM	0.966	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.24	2.00	8.25	10.00	[0 - 30]
payoutRatioTTM	0.217	1.500	7.83	-7.83	[0 - 1]
pegRatioTTM	-0.773	1.500	-8.49	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.275	1.000	5.63	0	[0.1 - 0.5]
Total Score				5.25

Zoetis Inc

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.